Biogen, Inc. (BIIB)
173.72
+1.10
(+0.64%)
USD |
NASDAQ |
Jan 22, 15:57
Biogen Cash from Investing (Quarterly): -35.10M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly & Co. | -2.983B |
| AbbVie, Inc. | -3.264B |
| Stoke Therapeutics, Inc. | 9.094M |
| Alnylam Pharmaceuticals, Inc. | 501.11M |
| Insmed, Inc. | -762.23M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 1.272B |
| Cash from Financing (Quarterly) | -130.20M |
| Free Cash Flow | 2.262B |
| Free Cash Flow Per Share (Quarterly) | 8.300 |
| Free Cash Flow to Equity (Quarterly) | 1.226B |
| Free Cash Flow to Firm (Quarterly) | 1.277B |
| Free Cash Flow Yield | 8.88% |